GlassScriptPhysician profile
Samrat Sanghvi
NPI 1811422637
$6,951.15
in general payments reported to CMS, 2019-2025
50 companies · $2,972 in 2025
The $2,972 reported for 2025 was more than what 93% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,356 · 2023: $2,230 · 2024: $394 · 2025: $2,972.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,911 · Consulting Fee: $2,684.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,911.47 |
| Consulting Fee | $2,684.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $1,820.83 | 2023-2025 | Enhertu, Datroway, Injectafer |
| Janssen Biotech, INC. | $1,659.68 | 2022-2025 | Tecvayli, Darzalex, Imbruvica |
| Novartis Pharmaceuticals Corporation | $571.46 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $287.68 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $250.88 | 2022-2025 | Lynparza, Imfinzi |
| Pfizer INC. | $208.61 | 2022-2025 | |
| Siemens Medical Solutions USA, INC. | $202.52 | 2022-2024 | Truebeam, Eclipse Treatment Planning System For External Beam Radiation Therapy |
| Incyte Corporation | $167.83 | 2022-2025 | Jakafi, Zynyz, Monjuvi |
| Takeda Pharmaceuticals U.S.A., INC. | $123.18 | 2023-2025 | Alunbrig, Fruzaqla, Iclusig |
| Genzyme Corporation | $115.31 | 2022-2025 | |
| Glaxosmithkline, LLC. | $99.26 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Seagen INC. | $94.40 | 2022-2023 | Tukysa, Padcev |
| Amgen INC. | $85.51 | 2022-2023 | Xgeva, Nplate, Vectibix |
| Regeneron Healthcare Solutions, INC. | $80.17 | 2023-2025 | Libtayo |
| Emd Serono, INC. | $79.39 | 2022-2025 | Bavencio, Tepmetko |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samrat Sanghvi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.